PITTSBURGH, Nov. 7, 2016 /PRNewswire/ -- A new peer-reviewed study published today in the Journal of Pain Research indicates that Wobenzym®, an oral enzyme combination (OEC) containing proteolytic enzymes and bioflavonoid, showed comparable efficacy and a superior tolerability and safety profile — associated with a significantly lower risk of treatment-emergent adverse events — compared to nonselective nonsteroidal anti-inflammatory drug (NSAID) Diclofenac in the treatment of osteoarthritis of the knee.
Osteoarthritis of the knee affects, on average, 25 percent of the general population in the Western world and is the most prevalent cause of pain and locomotor disability worldwide. Researchers at the Institute of Neurological Sciences, Nuremberg; Interdisciplinary Center for Pain and Palliative Care Medicine, Göppingen; Interdisciplinary Center for Rheumatology and Immunology, Frankfurt; and O. Meany Consultancy, Hamburg, Germany, conducted this meta-analysis of six different double-blind, comparator-controlled intervention studies of Wobenzym® versus NSAIDs in osteoarthritis. In the meta-analysis, the authors report that while treatment with both OECs and NSAIDs resulted in significant and comparable improvements in pain, function and daily living as compared to baseline, OEC treatment resulted in significantly fewer treatment-emergent adverse effects (TEAEs), and virtually no change in key hepatic enzymes, a common side effect of NSAID treatment. "Our analysis concludes that Wobenzym® is a safe and effective alternative to NSAIDs in the management of pain and is better tolerated by patients," said lead researcher Michael Überall, of the Institute of Neurological Sciences. "We are encouraged by the results, which indicate that a safer alternative exists for patients who may have discontinued NSAID use due to adverse effects and still struggle with the pain of osteoarthritis of the knee."